Loading...
•
Sep 30, 2024
Co-Diagnostics Q3 2024 Earnings Report
Reported financial results for the quarter ended September 30, 2024.
Key Takeaways
Co-Diagnostics announced their Q3 2024 financial results, highlighting progress in their pipeline development and ongoing dialogue with the FDA regarding their 510(k) application.
Maintained active dialogue with the FDA throughout their substantive review of 510(k) application.
Advanced all tests in pipeline towards completion, regulatory submission, and commercialization.
Believe that COVID-19, tuberculosis, multiplex respiratory, and HPV multiplex tests on the Co-Dx PCR platform have the potential to increase access to state-of-the-art PCR diagnostics.
Team working hard to make mission a reality and drive test developments forward.
Co-Diagnostics
Co-Diagnostics
Forward Guidance
Co-Diagnostics is making significant progress on tests and looks forward to providing regulatory and commercialization updates as they develop.